{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:02:45Z","timestamp":1789405365252,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1124\/jpet.105.094474","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T04:48:32Z","timestamp":1137646112000},"page":"1378-1385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Do Subtype-Selective \u03b3-Aminobutyric AcidA Receptor Modulators Have a Reduced Propensity to Induce Physical Dependence in Mice?"],"prefix":"10.1016","volume":"316","author":[{"given":"N.R.","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.\u00d8.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.094474_bib1","doi-asserted-by":"crossref","unstructured":"Atack JR (2003) Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord 2: 213\u2013232.","DOI":"10.2174\/1568007033482841"},{"key":"10.1124\/jpet.105.094474_bib2","doi-asserted-by":"crossref","unstructured":"Busto U, Kaplan HL, Zawertailo L, and Sellers EM (1994) Pharmacologic effects and abuse liability of bretazenil, diazepam and alprazolam in humans. Clin Pharmacol Ther 55: 451\u2013463.","DOI":"10.1038\/clpt.1994.55"},{"key":"10.1124\/jpet.105.094474_bib3","unstructured":"Chouinard G (2004) Issues in the clinical use of benzodiazepines: potency, withdrawal and rebound. J Clin Psychiatry 65 (Suppl 5): 7\u201312."},{"key":"10.1124\/jpet.105.094474_bib4","unstructured":"Dollery C, editor (1999) Therapeutic Drugs, 2nd ed, Churchill Livingstone, Edinburgh, UK."},{"key":"10.1124\/jpet.105.094474_bib5","doi-asserted-by":"crossref","unstructured":"Faure-Halley C, Graham D, Arbilla S, and Langer SZ (1993) Expression and properties of recombinant alpha 1 beta 2 gamma 2 and alpha 5 beta 2 gamma 2 forms of the rat GABAA receptor. Eur J Pharmacol 246: 283\u2013287.","DOI":"10.1016\/0922-4106(93)90043-9"},{"key":"10.1124\/jpet.105.094474_bib6","doi-asserted-by":"crossref","unstructured":"Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Francon D, Avenet P, Depoortere H, Tan S, et al. (2001) SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther 298: 753\u2013768.","DOI":"10.1016\/S0022-3565(24)29437-4"},{"key":"10.1124\/jpet.105.094474_bib7","doi-asserted-by":"crossref","unstructured":"Haefely W, Martin JR, and Schoch P (1990) Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 11: 452\u2013456.","DOI":"10.1016\/0165-6147(90)90126-S"},{"key":"10.1124\/jpet.105.094474_bib8","doi-asserted-by":"crossref","unstructured":"Hajak G, Muller WE, Wittchen HU, Pittrow D, and Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98: 1371\u20131378.","DOI":"10.1046\/j.1360-0443.2003.00491.x"},{"key":"10.1124\/jpet.105.094474_bib9","doi-asserted-by":"crossref","unstructured":"Jensen LH, Petersen EN, and Braestrup C (1983) Audiogenic seizures in DBA\/2 mice discriminate sensitively between low efficacy benzodiazepine receptor agonists and inverse agonists. Life Sci 33: 393\u2013399.","DOI":"10.1016\/S0024-3205(83)80014-9"},{"key":"10.1124\/jpet.105.094474_bib10","doi-asserted-by":"crossref","unstructured":"Johansen TH, Drejer J, W\u00e4tjen F, and Nielsen E\u00d8 (1993) A novel non-NMDA receptor antagonist shows selective displacement of low-affinity [3H]kainate binding. Eur J Pharmacol 246: 195\u2013204.","DOI":"10.1016\/0922-4106(93)90031-4"},{"key":"10.1124\/jpet.105.094474_bib11","doi-asserted-by":"crossref","unstructured":"Little HJ, Gale R, Sellars N, Nutt DJ, and Taylor SC (1988) Chronic benzodiazepine treatment increases the effects of the inverse agonist FG7142. Neuropharmacology 27: 383\u2013389.","DOI":"10.1016\/0028-3908(88)90147-5"},{"key":"10.1124\/jpet.105.094474_bib12","doi-asserted-by":"crossref","unstructured":"Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, Fritschy JM, Rulicke T, Bluethmann H, Mohler H, et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science (Wash DC) 290: 131\u2013134.","DOI":"10.1126\/science.290.5489.131"},{"key":"10.1124\/jpet.105.094474_bib13","doi-asserted-by":"crossref","unstructured":"Martin JR, Jenck F, and Moreau JL (1995) Comparison of benzodiazepine receptor ligands with partial agonistic, antagonistic or partial inverse agonistic properties in precipitating withdrawal in squirrel monkeys. J Pharmacol Exp Ther 275: 405\u2013411.","DOI":"10.1016\/S0022-3565(25)12064-8"},{"key":"10.1124\/jpet.105.094474_bib14","unstructured":"Mathiesen C, Hartz BP, Nielsen E\u00d8, Johansen TH, and Mirza NR (2003) NS2664: an atypical benzodiazepine site ligand: profile in animal models of epilepsy. Behav Pharmacol 14: S47."},{"key":"10.1124\/jpet.105.094474_bib15","doi-asserted-by":"crossref","unstructured":"McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3: 587\u2013592.","DOI":"10.1038\/75761"},{"key":"10.1124\/jpet.105.094474_bib16","unstructured":"Mirza NR, Watjen F, Hartz BP, Teuber L, Nielsen E\u00d8, Mathiasen LI, Johansen TH, and Jensen LH (2003) NS2710: a novel anxiolytic with a dual mechanism of action. Behav Pharmacol 14: S24."},{"key":"10.1124\/jpet.105.094474_bib17","doi-asserted-by":"crossref","unstructured":"Nutt DJ (2005) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 10: 49\u201356.","DOI":"10.1017\/S1092852900009901"},{"key":"10.1124\/jpet.105.094474_bib18","doi-asserted-by":"crossref","unstructured":"Perrault G, Morel E, Sanger DJ, and Zivkovic B (1992) Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 263: 298\u2013303.","DOI":"10.1016\/S0022-3565(25)10339-X"},{"key":"10.1124\/jpet.105.094474_bib19","doi-asserted-by":"crossref","unstructured":"Pieri L, Hunkeler W, Jauch R, Merz WA, Roncari G, and Timm U (1988) Bretazenil. Drugs Future 13: 730\u2013735.","DOI":"10.1358\/dof.1988.013.08.63039"},{"key":"10.1124\/jpet.105.094474_bib20","doi-asserted-by":"crossref","unstructured":"Richards JG and Martin JR (1998) Binding profiles and physical dependence liabilities of selected benzodiazepine receptor ligands. Brain Res Bull 45: 381\u2013387.","DOI":"10.1016\/S0361-9230(97)00370-5"},{"key":"10.1124\/jpet.105.094474_bib21","doi-asserted-by":"crossref","unstructured":"Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, and Mohler H (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature (Lond) 401: 796\u2013800.","DOI":"10.1038\/44579"},{"key":"10.1124\/jpet.105.094474_bib22","doi-asserted-by":"crossref","unstructured":"Sanger DJ and Benavides J (1993) Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system. Psychopharmacology (Berl) 111: 315\u2013322.","DOI":"10.1007\/BF02244947"},{"key":"10.1124\/jpet.105.094474_bib23","doi-asserted-by":"crossref","unstructured":"Shaw SH, Curson H, and Coquelin JP (1992) A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric inpatients. J Int Med Res 20: 150\u2013161.","DOI":"10.1177\/030006059202000207"},{"key":"10.1124\/jpet.105.094474_bib24","doi-asserted-by":"crossref","unstructured":"Sieghart W (1995) Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 47: 181\u2013234.","DOI":"10.1016\/S0031-6997(25)06840-1"},{"key":"10.1124\/jpet.105.094474_bib25","doi-asserted-by":"crossref","unstructured":"Vgontzas AN, Kales A, and Bixler EO (1995) Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 51: 205\u2013223.","DOI":"10.1159\/000139363"},{"key":"10.1124\/jpet.105.094474_bib26","doi-asserted-by":"crossref","unstructured":"Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, and Hohagen F (2001) A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci 251: 117\u2013123.","DOI":"10.1007\/s004060170045"},{"key":"10.1124\/jpet.105.094474_bib27","doi-asserted-by":"crossref","unstructured":"Volkow ND, Wang GJ, Fowler JS, Learned-Coughlin S, Yang J, Logan J, Schlyer D, Gatley JS, Wong C, Zhu W, et al. (2005) The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry 57: 640\u2013646.","DOI":"10.1016\/j.biopsych.2004.12.007"},{"key":"10.1124\/jpet.105.094474_bib28","doi-asserted-by":"crossref","unstructured":"von Voigtlander PF and Lewis RA (1991) A rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice: evaluation of benzodiazepine-related agonists and partial agonists. J Pharmacol Methods 26: 1\u20135.","DOI":"10.1016\/0160-5402(91)90049-B"},{"key":"10.1124\/jpet.105.094474_bib29","doi-asserted-by":"crossref","unstructured":"Weerts EM, Ator NA, Grech DM, and Griffiths RR (1998) Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther 285: 41\u201353.","DOI":"10.1016\/S0022-3565(24)37370-7"},{"key":"10.1124\/jpet.105.094474_bib30","unstructured":"Woods JH, Katz JL, and Winger G (1995) Abuse and therapeutic use of benzodiazepines and benzodiazepines-like drugs, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds), Raven Press Ltd., New York."},{"key":"10.1124\/jpet.105.094474_bib31","doi-asserted-by":"crossref","unstructured":"Yanagita T (1983) Dependence potential of zopiclone studied in monkeys. Pharmacology 51: 216\u2013227.","DOI":"10.1159\/000137930"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524325650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524325650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.094474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:48:00Z","timestamp":1740001680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524325650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0022356524325650"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.094474","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do Subtype-Selective \u03b3-Aminobutyric AcidA Receptor Modulators Have a Reduced Propensity to Induce Physical Dependence in Mice?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.094474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}